methylphenidate has been researched along with Besnier-Boeck Disease in 4 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Fatigue and Sarcoidosis-Treatment with Methylphenidate study is a randomised, controlled, parallel-arm and feasibility trial of methylphenidate for the treatment of sarcoidosis-associated fatigue." | 9.24 | Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol. ( Atkins, C; Clark, AB; Fordham, R; Jones, AP; Stockl, A; Wilson, AM, 2017) |
| "The Fatigue and Sarcoidosis-Treatment with Methylphenidate study is a randomised, controlled, parallel-arm and feasibility trial of methylphenidate for the treatment of sarcoidosis-associated fatigue." | 5.24 | Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol. ( Atkins, C; Clark, AB; Fordham, R; Jones, AP; Stockl, A; Wilson, AM, 2017) |
| "Trial evidence for treating fatigue as a manifestation of sarcoidosis is limited and requires further investigation." | 2.55 | Managing fatigue in sarcoidosis - A systematic review of the evidence. ( Atkins, C; Wilson, AM, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkins, C | 3 |
| Jones, A | 1 |
| Clark, AB | 2 |
| Stockl, A | 2 |
| Fordham, R | 2 |
| Wilson, AM | 3 |
| Jones, AP | 1 |
| Wagner, MT | 1 |
| Marion, SD | 1 |
| Judson, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate[NCT02643732] | 30 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for methylphenidate and Besnier-Boeck Disease
| Article | Year |
|---|---|
Managing fatigue in sarcoidosis - A systematic review of the evidence.
Topics: Adalimumab; Antirheumatic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Exercise | 2017 |
3 trials available for methylphenidate and Besnier-Boeck Disease
| Article | Year |
|---|---|
Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial.
Topics: Double-Blind Method; Fatigue; Feasibility Studies; Humans; Methylphenidate; Sarcoidosis | 2021 |
Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol.
Topics: Central Nervous System Stimulants; Chronic Disease; Double-Blind Method; England; Fatigue; Feasibili | 2017 |
The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis.
Topics: Algorithms; Attention; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylpheni | 2005 |